质子加速部分乳腺照射治疗0-IIA期乳腺癌女性患者的1/2期试验五年结果
该1/2期试验评估质子外照射部分乳腺照射治疗0-IIA期乳腺癌的可行性与疗效。1期部分12例患者全部达到可行性标准;2期部分实际入组28例患者共29个治疗乳腺,因新冠疫情提前终止。中位随访5.4年,仅1例局部复发,无≥3级急性或晚期毒性,但2年美容效果未达预设目标。
要点
- 质子加速部分乳腺照射采用3.85 Gy每日两次至38.5 Gy,可行且急性和长期毒性极低。
- 2期部分因新冠疫情提前终止,实际入组28例患者共29个治疗乳腺,原计划45例。
- 2年医生评定美容效果优秀56%、良好19%、一般25%,未达到优秀或良好>85%的预设目标。
核心结论
- 质子加速部分乳腺照射每日两次分割方案可行,并与极低的急性和长期毒性相关。
- 但该试验未达到美容效果目标并提前终止,未来需研究确定笔束扫描质子或不同分割方案能否改善这些结果。
研究设计与样本
- 1/2期试验,纳入0-IIA期乳腺癌患者,条件为pTis-T2、N0、肿瘤大小≤3 cm。
- 1期部分12例患者,以计划成功创建、治疗实施和急性≥3级毒性≤20%为可行性标准。
- 2期部分原计划45例,实际入组28例患者共29个治疗乳腺(1例双侧),因新冠疫情停止入组且未重新开放。
主要发现
- 1期部分全部4项必需可行性标准均达到。
- 40例患者中位随访5.4年(范围2.3-8.6年),共1例局部复发。
- 无≥3级急性或晚期毒性。
- 基线时所有患者医生评定美容效果为良好或优秀,2年时优秀56%、良好19%、一般25%。
- 38个乳腺接受双散射质子治疗,3个接受笔束扫描质子治疗。
关键数值与推荐
- 质子束放疗剂量为3.85 Gy每日两次,总剂量38.5 Gy。
- 1期可行性标准包括计划成功创建、治疗实施和急性≥3级毒性≤20%。
- 2期疗效目标为急性≥3级毒性≤20%以及2年医生评定美容效果优秀或良好>85%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因新冠疫情停止入组并提前终止,2期部分实际入组28例患者共29个治疗乳腺,低于原计划45例。
- 试验未达到美容效果目标。
- 未来需研究确定笔束扫描质子或不同分割方案能否改善这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report the results of a phase 1/2 trial of external beam partial breast radiation using proton therapy. METHODS AND MATERIALS: Eligible patients included stage 0-IIA breast cancer pTis-T2, N0, and size ≤3 cm. Proton beam radiation was used to deliver 3.85 Gy twice daily to 38.5 Gy. The phase 1 portion determined feasibility based on criteria of successful plan creation, treatment delivery, and acute toxicity grade ≥3 in ≤20% of patients. The phase 2 portion had efficacy goals of acute toxicity grade ≥3 in ≤20% of patients and observing physician-rated cosmesis of excellent or good >85% of patients at 2 years. RESULTS: From April 2013 to March 2015, there were 12 patients enrolled onto the phase 1 portion, and the preplanned analysis of feasibility was met in all 4 required criteria. From July 2015 through December 2019 there were 28 patients with 29 treated breasts (1 bilateral) enrolled onto the phase 2 portion of the trial out of 45 originally planned. The trial was closed to accrual because of the coronavirus pandemic and not reopened. Thirty-eight breasts were treated with double-scattering and 3 pencil-beam scanning protons. The median follow-up of the 40 patients is 5.4 years (range, 2.3-8.6 years). There was 1 local recurrence. There was no grade ≥3 acute or late toxicity. At baseline all patients had physician-rated cosmesis good or excellent but at 2 years was excellent in 56%, good in 19%, and fair in 25%. CONCLUSIONS: Proton-accelerated partial breast irradiation delivered with a twice-daily fractionation was feasible and associated with very low acute and long-term toxicity. However, the trial did not meet goals for cosmesis outcomes and was closed prematurely. Future study is needed to determine whether pencil-beam scanning protons or different fractionation could improve these outcomes.
引用
- Freedman GM, Li T, Garver E, et al. Five-Year Outcomes of a Phase 1/2 Trial of Accelerated Partial Breast Irradiation Using Proton Therapy for Women With Stage 0-IIA Breast Cancer. Adv Radiat Oncol. 2023. PMID: 38405317. doi:10.1016/j.adro.2023.101334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。